Article
Public, Environmental & Occupational Health
Joyce Kong, Francisco Cuevas-Castillo, Mahmoud Nassar, Chi M. Lei, Zarwa Idrees, William C. Fix, Caroline Halverstam, Adnan Mir, Amira Elbendary, Alwin Mathew
Summary: In December 2020, Moderna released the mRNA-1273 vaccine with common side effects like headache and muscle pain. A case of a 66-years-old man developing a bullous rash after receiving a commercial COVID-19 mRNA vaccine was reported, with symptoms appearing 24 hours after the second dose. The skin biopsy indicated an extensive bullous fixed drug eruption related to the Moderna vaccination.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2021)
Article
Clinical Neurology
Peter Tatum
Summary: This report describes a case of a 56-year-old male who developed unilateral right thigh numbness after receiving his second Moderna COVID-19 vaccine. A raised, painless area with a red border appeared in the center of the thigh after one week and resolved spontaneously after 2 weeks. This is the first documented case of meralgia paresthetica following COVID-19 vaccination without any other risk factors. COVID vaccines may be a potential cause of localized peripheral neuropathy.
NEUROLOGICAL SCIENCES
(2023)
Article
Immunology
Linh-An C. Tuong, Peter Capucilli, Mary Staicu, Allison Ramsey, Edward E. Walsh, S. Shahzad Mustafa
Summary: Administering the second dose of Moderna and Pfizer-BioNTech COVID-19 vaccines in a graded manner to patients with immediate hypersensitivity reactions to the first dose ensures safety and immunogenicity.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Immunology
Isabel Garrido, Susana Lopes, Manuel Sobrinho Simoes, Rodrigo Liberal, Joanne Lopes, Fatima Carneiro, Guilherme Macedo
Summary: The case of acute severe autoimmune hepatitis following COVID-19 vaccination highlights the importance of closely monitoring adverse reactions during the vaccination process to ensure safety. Healthcare providers must remain vigilant during mass COVID-19 vaccination to detect and manage potential complications promptly.
JOURNAL OF AUTOIMMUNITY
(2021)
Letter
Medicine, General & Internal
Joanne Lacy, Sue Pavord, Kevin E. Brown
Summary: Forty individuals who developed thrombosis and thrombocytopenia after initial vaccination with ChAdOx1 nCoV-19 were given a second dose of a different Covid-19 vaccine, predominantly BNT162b2, and did not experience a recurrence of thrombosis and thrombocytopenia.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Emergency Medicine
Kah-Meng Chong, Ching-Yao Yang, Chien-Chin Lin, Wan-Ching Lien
Summary: We report a rare case of severe immune thrombocytopenia in an Asian woman following the administration of the Moderna COVID-19 vaccine. This highlights a potential adverse effect of mRNA-based vaccines in cancer patients receiving immune checkpoint inhibitors.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2022)
Article
Immunology
Vladimir Atanasov, Natalia Barreto, Jeff Whittle, John Meurer, Benjamin W. W. Weston, Qian Eric Luo, Andy Ye Yuan, Lorenzo Franchi, Ruohao Zhang, Bernard Black
Summary: Prior research shows that Pfizer and Moderna COVID-19 vaccines offer similar protection against mortality, with Pfizer having a slight advantage. However, most comparisons did not consider the selection effects of vaccine recipients. This study provides evidence of large selection effects and introduces a novel method to control for these effects. The results show that Pfizer has a higher relative mortality risk compared to Moderna for individuals aged 60 and above, but the difference is smaller and not statistically significant for booster recipients. The study also suggests the possibility of a higher vaccine dose for older individuals.
Article
Multidisciplinary Sciences
Joao Faro-Viana, Marie-Louise Bergman, Ligia A. Goncalves, Nadia Duarte, Teresa P. Coutinho, Patricia C. Borges, Christian Diwo, Rute Castro, Paula Matoso, Vanessa Malheiro, Ana Brennand, Lindsay Kosack, Onome Akpogheneta, Joao M. Figueira, Conceicao Cardoso, Ana M. Casaca, Paula M. Alves, Telmo Nunes, Carlos Penha-Goncalves, Jocelyne Demengeot
Summary: This study analyzed the humoral immune response induced by the BNT162b2 vaccine in different age groups and found that the immunogenicity after a single dose skewed towards IgG and decreased with increasing age. The second dose of the vaccine normalized the IgG response. These findings highlight the importance of administering two doses of mRNA vaccines to achieve population-scale humoral immunity, and suggest the need for timely monitoring of elderly and immunosuppressed individuals who receive the vaccine.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, General & Internal
Eleftheria Vasileiou, Colin R. Simpson, Ting Shi, Steven Kerr, Utkarsh Agrawal, Ashley Akbari, Stuart Bedston, Jillian Beggs, Declan Bradley, Antony Chuter, Simon de Lusignan, Annemarie B. Docherty, David Ford, F. D. Richard Hobbs, Mark Joy, Srinivasa Vittal Katikireddi, James Marple, Colin McCowan, Dylan McGagh, Jim McMenamin, Emily Moore, Josephine L. K. Murray, Jiafeng Pan, Lewis Ritchie, Syed Ahmar Shah, Sarah Stock, Fatemeh Torabi, Ruby S. M. Tsang, Rachael Wood, Mark Woolhouse, Chris Robertson, Aziz Sheikh
Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.
Article
Immunology
Harapan Harapan, Raisha Fathima, Hendrix Indra Kusuma, Samsul Anwar, Widhy Yudistira Nalapraya, Adityo Wibowo, Ketut Dewi Kumara Wati, Ayunda Medina, Anna Hanifa Defrita, Yesi Astri, Arie Prasetyowati, Nurfarahin Nurfarahin, Afriyani Khusna, Setya Oktariana, Sarifuddin Anwar, Milza Oka Yussar, Siti Khotimah, Bahagia Willibrordus Maria Nainggolan, Putri Rizki Amalia Badri, Raden Argarini, Wira Winardi, Rosaria Indah, Malik Sallam, Yogambigai Rajamoorthy, Abram L. Wagner, Mudatsir Mudatsir
Summary: The acceptance of COVID-19 vaccine booster doses in Indonesia is influenced by factors such as lack of knowledge, concerns about side effects, and worries about the halal status of the vaccines. More campaigns are needed to increase acceptance.
Article
Immunology
Georgios Zoumpoulis, Paraskevi Deligiorgi, Dimitrios Lamprinos, Panagiotis Georgakopoulos, Evangelos Oikonomou, Gerasimos Siasos, Georgios Rachiotis, Christos Damaskos, Dimitrios Papagiannis, Kostas A. Papavassiliou, George Patoulis, Fotios Patsourakos, Vasiliki Benetou, Elena Riza, Philippos Orfanos, Pagona Lagiou, Georgios Marinos
Summary: Limited data on attitudes and acceptance of the fourth dose of COVID-19 vaccination among physicians in Athens were collected. Results showed that about half of the surveyed physicians did not receive the fourth dose, mainly due to the lack of obligation, history of three doses, and insufficient information on effectiveness. However, more than half of those who had received three doses were willing to receive the fourth dose in the future.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Hung-Pin Chan, Daniel Hueng-Yuan Shen, Ming-Hui Yang, Chin Hu, Yu-Chang Tyan
Summary: We present a case of a 71-year-old man with a history of thyroid cancer and renal cell carcinoma who developed chest tightness and pain after receiving the Moderna COVID-19 vaccine. Myocardial perfusion imaging revealed focal uptake in the left axillary region, which was found to be enlarged benign lymph nodes on SPECT/CT. The diagnosis is consistent with reactive hyperplasia following vaccination.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Soulaimane Berkane, Intissar Harizi, Abdelhamid Tayebi, Michael S. Silverman, Saverio Stranges
Summary: This study explores the optimal vaccination strategy in the context of vaccine shortage. The results show that in a two-dose regimen, delaying the second dose as much as possible is the optimal strategy if the efficacy of the second dose is less than or equal to twice the efficacy of the first dose. In the general case, the optimal strategy is to administer the dose corresponding to the maximum inter-dose efficacy difference.
INTERNATIONAL JOURNAL OF PUBLIC HEALTH
(2022)
Review
Immunology
Khaled Albakri, Abdulrhman Khaity, Hany Atwan, Othman Saleh, Momen Al-Hajali, Shirin Cadri, Rehab Adel Diab, Ebraheem Albazee, Ahmed Negida
Summary: A systematic review found that there is a small risk of Bell's palsy after COVID-19 vaccination, with a rate of 25.3 per million people. The majority of cases occurred after the first dose, particularly with Pfizer, AstraZeneca, and Sputnik V vaccines. Patients treated with corticosteroids, IVIG, and anti-viral drugs showed significant improvement. Overall, the benefits of vaccination outweigh the potential risks.
Article
Immunology
Mehmet Akif Sezerol, Selin Davun
Summary: This study surveyed 2383 older adults aged 65-75 who had not received the third dose of the COVID-19 vaccine. The study found that vaccination willingness was associated with factors such as vaccination beliefs, gender, age, education level, and forgetfulness. The results show the importance of informing older adults about the risks of not being vaccinated and the potential benefits of additional doses in reducing mortality rates.
